Cathepsin S inhibitors

a cathepsin and inhibitor technology, applied in the field of peptidyl compounds, can solve the problems of increasing the likelihood of toxicity

Active Publication Date: 2008-12-16
BOEHRINGER INGELHEIM PHARMA INC
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

An irreversible compound could therefore permanently inactivate a non-target enzyme, increasing the likelihood of toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cathepsin S inhibitors
  • Cathepsin S inhibitors
  • Cathepsin S inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of 2-tert-butoxycarbonylamino-4,4,5,5-trimethyl-hexanoic acid

[0086]

[0087]Lithium diisopropylamide (LDA) (1.5 M solution in cyclohexane / THF / ethylbenzene) (106 mL, 160 mmol, 1.15 equiv) was syringed into a 1000 mL round-bottom flask under a blanket of Ar. Dry THF (150 mL) was added and the mixture was cooled to −78° C. with a dry-ice / acetone bath. 3,3-Dimethyl-butanoic acid ethyl ester (20 g, 23.3 mL, 139 mmol, 1.0 equiv) was added dropwise from a syringe over a 10 min period followed by stirring at −78° C. for 1 h. Methyl iodide (9.5 mL, 152 mmol, 1.1 equiv) was added dropwise from a syringe over a 10 min period and the creamy mixture was stirred for 1 h at −78° C., resulting in a very thick mixture. The dry-ice bath was removed and replaced with an ice bath at 0° C. Another 150 mL of dry THF was added followed by another addition of LDA (106 mL, 160 mmol, 1.15 equiv). The resulting mixture was stirred for 10 min and then the flask was re-immersed in a dry-ice / acetone bath....

example 2

Synthesis of 2-tert-butoxycarbonylamino-5,5-dimethyl-heptanoic acid

[0093]

[0094]3,3-Dimethyl-pent-4-enoic acid methyl ester (20.0 mL, 126 mmol, 1.00 eq) was cautiously introduced via pipet into a 2 L flask containing a suspension of LiAlH4 (3.63 g, 96 mmol, 0.76 eq) in 500 mL of anhydrous diethyl ether cooled by an ice water bath. The reaction mixture was allowed to warm to room temperature overnight while stirring, then quenched by slow addition of a saturated sodium potassium tartrate solution (150 mL). The mixture was diluted with ether (200 mL), and the organic layer was separated, dried (MgSO4), and concentrated to provide 3,3-dimethyl-pent-4-en-1-ol as a colorless liquid (11.0 g, 76% yield). This material was used without further purification; 1H NMR (CDCl3, 400 MHz) δ 1.00 (s, 6H), 1.58 (t, J=7.3 Hz, 2H), 2.07 (s, 1H), 3.59 (t, J=7.3 Hz, 2H), 4.89-4.94 (m, 2H), 5.80 (dd, J=17.3, 14.1, 1H).

[0095]Anhydrous DMSO (17.1 mL, 241 mmol, 2.5 eq) was added dropwise to a solution of oxal...

example 3

Synthesis of (S)-2-tert-butoxycarbonylamino-5,5-dimethyl-heptanoic acid

[0099]

[0100]R,R-DIPAMP cyclooctadiene Rh(I) tetrfluoroborate (190 mg, 0.25 mmol, 0.04 eq) was added to a solution of (Z)-2-benzyloxycarbonylamino-5,5-dimethyl-hepta-2,6-dienoic acid methyl ester (2.00 g, 6.30 mmol, 1.00 eq) in dry methanol (20 mL) in a Paar hydrogenation flask. The reaction vessel was evacuated and flushed with a hydrogen atmosphere three times, then vigorously shaken under 50 psi of hydrogen overnight. The reaction mixture was concentrated in vacuo then filtered through a plug of silica gel using a gradient of ethyl acetate in hexanes as the eluant to provide (S)-2-benzyloxycarbonylamino-5,5-dimethyl-heptanoic acid methyl ester as a yellow oil (1.63 g, 81% yield); 1H NMR (CDCl3, 400 MHz) δ 0.74-0.90 (m, 9H), 1.10-1.30 (m, 4H), 1.58-1.70 (m, 1H), 1.75-1.90 (m, 1H), 3.75 (s, 3H), 4.30-4.40 (m, 1H), 5.14 (s, 2H), 5.24-5.33 (m, 1H), 7.30-7.37 (m, 5H); [α]20D=+15.57 c=2.00, CHCl3.

[0101]10% Pd / C catal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them.

Description

APPLICATION DATA[0001]This application is a continuation in-part of U.S. application Ser. No. 10 / 790,549 filed Mar. 1, 2004 which claims benefit to U.S. provisional application No. 60 / 454,239 filed Mar. 13, 2003.TECHNICAL FIELD OF THE INVENTION[0002]This invention relates to peptidyl compounds active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them.BACKGROUND OF THE INVENTION[0003]Cathepsin S is a member of the papain family, within the papain superfamily of cysteine proteases. The papain family is the largest group of cysteine proteases and includes proteases such as cathepsins B, H, K, L, O and S. (A. J. Barrett et al., 1996, Perspectives in Drug Discovery and Design, 6, 1). The cysteine proteases have important roles in human...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityPatents(United States)
IPC IPC(8): A61K31/4465C07D401/12C07D211/66C07D413/12
CPCC07D211/66C07D413/12
InventorHICKEY, EUGENE R.LIU, WIEMENSUN, SANXINGWARD, YANCEY DAVIDYOUNG, ERICK RICHARD ROUSH
OwnerBOEHRINGER INGELHEIM PHARMA INC